Literature DB >> 18540739

Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.

Rachel Manber1, Helena C Kraemer, Bruce A Arnow, Madhukar H Trivedi, A John Rush, Michael E Thase, Barbara O Rothbaum, Daniel N Klein, James H Kocsis, Alan J Gelenberg, Martin E Keller.   

Abstract

The main aim of the present novel reanalysis of archival data was to compare the time to remission during 12 weeks of treatment of chronic depression following antidepressant medication (n = 218), psychotherapy (n = 216), and their combination (n = 222). Cox regression survival analyses revealed that the combination of medication and psychotherapy produced full remission from chronic depression more rapidly than either of the single modality treatments, which did not differ from each other. Receiver operating characteristic curve analysis was used to explore predictors (treatment group, demographic, clinical, and psychosocial) of remission. For those receiving the combination treatment, the most likely to succeed were those with low baseline depression (24-item Hamilton Rating Scale for Depression [HRSD; M. Hamilton, 1967] score < 26) and those with high depression scores but low anxiety (HRSD = 26 and Hamilton Anxiety Rating Scale [M. Hamilton, 1959] < 14). Both profiles were associated with at least 40% chance of attaining full remission. The model did not identify predictors for those receiving medication or psychotherapy alone, and it did not distinguish between the 2 monotherapies. The authors conclude that combined antidepressant medications and psychotherapy result in faster full remission of chronic forms of major depressive disorder. (c) 2008 APA, all rights reserved

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540739      PMCID: PMC3694578          DOI: 10.1037/0022-006X.76.3.459

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  41 in total

Review 1.  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.

Authors:  I M Anderson; D J Nutt; J F Deakin
Journal:  J Psychopharmacol       Date:  2000-03       Impact factor: 4.153

2.  Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.

Authors:  M E Thase; A R Entsuah; R L Rudolph
Journal:  Br J Psychiatry       Date:  2001-03       Impact factor: 9.319

Review 3.  The clinical, psychosocial, and pharmacoeconomic ramifications of remission.

Authors:  M E Thase
Journal:  Am J Manag Care       Date:  2001-09       Impact factor: 2.229

4.  Sertraline versus imipramine to prevent relapse in chronic depression.

Authors:  L M Koran; A J Gelenberg; S G Kornstein; R H Howland; R A Friedman; C DeBattista; D Klein; J H Kocsis; A F Schatzberg; M E Thase; A J Rush; R M Hirschfeld; L M LaVange; M B Keller
Journal:  J Affect Disord       Date:  2001-06       Impact factor: 4.839

5.  Predictors of 1-year outcome in depression.

Authors:  G Parker; K Wilhelm; P Mitchell; G Gladstone
Journal:  Aust N Z J Psychiatry       Date:  2000-02       Impact factor: 5.744

6.  A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

Authors:  M B Keller; J P McCullough; D N Klein; B Arnow; D L Dunner; A J Gelenberg; J C Markowitz; C B Nemeroff; J M Russell; M E Thase; M H Trivedi; J Zajecka
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

7.  Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.

Authors:  C M Beasley; M E Nilsson; S C Koke; J S Gonzales
Journal:  J Clin Psychiatry       Date:  2000-10       Impact factor: 4.384

8.  Psychosocial disability during the long-term course of unipolar major depressive disorder.

Authors:  L L Judd; H S Akiskal; P J Zeller; M Paulus; A C Leon; J D Maser; J Endicott; W Coryell; J L Kunovac; T I Mueller; J P Rice; M B Keller
Journal:  Arch Gen Psychiatry       Date:  2000-04

9.  Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations.

Authors:  M E Thase; J B Greenhouse; E Frank; C F Reynolds; P A Pilkonis; K Hurley; V Grochocinski; D J Kupfer
Journal:  Arch Gen Psychiatry       Date:  1997-11

10.  Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

Authors:  L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

View more
  14 in total

1.  Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial.

Authors:  Pamela H Mitchell; Richard C Veith; Kyra J Becker; Ann Buzaitis; Kevin C Cain; Michael Fruin; David Tirschwell; Linda Teri
Journal:  Stroke       Date:  2009-08-06       Impact factor: 7.914

2.  Depression treatment preferences of older white and Mexican origin men.

Authors:  Megan Dwight Johnson; Carolina Apesoa-Varano; Joel Hay; Jürgen Unutzer; Ladson Hinton
Journal:  Gen Hosp Psychiatry       Date:  2012-11-06       Impact factor: 3.238

Review 3.  A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2010-04-29       Impact factor: 7.616

4.  The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments.

Authors:  Michael E Thase; David Kingdon; Douglas Turkington
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

5.  Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.

Authors:  Michael W Otto; R Kathryn McHugh; Kathleen M Kantak
Journal:  Clin Psychol (New York)       Date:  2010-06-08

6.  Predictors of Response to Behavioral Treatments Among Children With ADHD-Inattentive Type.

Authors:  Elizabeth B Owens; Stephen P Hinshaw; Keith McBurnett; Linda Pfiffner
Journal:  J Clin Child Adolesc Psychol       Date:  2016-11-02

7.  COMORBIDITY BETWEEN DEPRESSIVE AND ADDICTIVE DISORDERS IN ADOLESCENTS: ROLE OF STRESS AND HPA ACTIVITY.

Authors:  Uma Rao
Journal:  US Psyc       Date:  2010-01-01

8.  Dysfunctional attitudes as a moderator of pharmacotherapy and psychotherapy for chronic depression.

Authors:  Stewart A Shankman; Miranda L Campbell; Daniel N Klein; Andrew C Leon; Bruce A Arnow; Rachel Manber; Martin B Keller; John C Markowitz; Barbara O Rothbaum; Michael E Thase; James H Kocsis
Journal:  J Psychiatr Res       Date:  2012-10-25       Impact factor: 4.791

9.  Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression.

Authors:  Dana Steidtmann; Rachel Manber; Christine Blasey; John C Markowitz; Daniel N Klein; Barbara O Rothbaum; Michael E Thase; James H Kocsis; Bruce A Arnow
Journal:  J Consult Clin Psychol       Date:  2013-06-10

10.  Effectiveness of cognitive behavioral therapy in public mental health: comparison to treatment as usual for treatment-resistant depression.

Authors:  Molly A Lopez; Monica A Basco
Journal:  Adm Policy Ment Health       Date:  2015-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.